Comparison of Elastic Tourniquet and Blood Pressure Cuff for Peripheral Intravenous Access in Hypotensive Patients: A Randomized Single-Blind Study
Abstract
Background: Peripheral intravenous catheterization (PIVC) is one of the most common invasive procedures performed in emergency departments (EDs). Elastic tourniquets (ET) and blood pressure cuffs (BPC) are most commonly used for venodilatation. Difficult vascular access can be predicted in some patients, and the rate of successful first-time PIVC placement in this group is low.
Objective: In this study, we investigated which venodilatation method is most appropriate for hypotensive patients, a group in whom vascular access is predicted to be difficult.
Methods: This was a prospective, single-blind, randomized controlled trial in the ED of a tertiary care hospital. Hypotensive patients were randomly assigned to two methods of administration. Patients' basilic vein diameters and venous collapsibility were measured before and after the intervention by a physician blinded to the intervention, followed by intravenous (IV) access. The primary outcome was the change in basilic vein diameter after the applied venodilatation method (ET or BPC), and the secondary outcomes were the change in vein collapsibility and initial access success rate.
Results: In this study of 101 patients, basilic vein diameter increased from 4.05 to 5.4 mm in the BPC group and from 4.1 to 4.5 mm in the ET group. The change in diameter in the BPC group was greater than that in the ET group (p < .0001). In addition, IV access was successful in 33 (63%) of 52 patients in the BPC group on the first attempt and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 101 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.